SCHEMBL29967592

SCHEMBL29967592

Cc1cn(-c2cc(NC(=O)c3ccc4c(c3)N(Cc3ccc5[nH]cnc5c3)CC4)cc(C(F)(F)F)c2)cn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR2E1 Q9Y466 6/20 0.53
▸ DDR1 Q08345 8/20 0.51
▸ DDR2 Q16832 5/20 0.51
▸ NTRK3 Q16288 4/20 0.51
▸ NTRK1 P04629 3/20 0.51
▸ NTRK2 Q16620 3/20 0.51
▸ ABL1 P00519 4/20 0.50
▸ KIT P10721 2/20 0.50
▸ PDGFRB P09619 1/20 0.50
▸ EPHB2 P29323 1/20 0.49
▸ LDLR P01130 1/20 0.49
▸ PCSK9 Q8NBP7 1/20 0.49
▸ BCR P11274 3/20 0.47
▸ MUSK O15146 1/20 0.47
▸ CDK11B P21127 1/20 0.47
▸ EPHA8 P29322 1/20 0.47
▸ CDK11A Q9UQ88 1/20 0.47
▸ RAF1 P04049 1/20 0.47
▸ BRAF P15056 1/20 0.47
▸ EPHB4 P54760 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27081785 1.00 NR2E1 (0.53) NR2E1DDR1DDR2NTRK3NTRK1
SCHEMBL27083082 0.87 ABL1 (0.54) NR2E1DDR1DDR2NTRK3NTRK1
SCHEMBL29967647 0.87 ABL1 (0.54) NR2E1DDR1DDR2NTRK3NTRK1
SCHEMBL29967557 0.86 MAPT (0.44) DDR1DDR2NTRK3NTRK1NTRK2
SCHEMBL27083027 0.86 MAPT (0.44) DDR1DDR2NTRK3NTRK1NTRK2
SCHEMBL29939696 0.86 DDR1 (0.65) NR2E1DDR1DDR2NTRK3NTRK1
SCHEMBL27082304 0.86 DDR1 (0.65) NR2E1DDR1DDR2NTRK3NTRK1
SCHEMBL27081687 0.84 DDR1 (0.54) NR2E1DDR1DDR2NTRK3NTRK1
SCHEMBL29940107 0.84 NR2E1 (0.54) NR2E1DDR1DDR2NTRK3NTRK1
SCHEMBL27082369 0.84 NR2E1 (0.54) NR2E1DDR1DDR2NTRK3NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4313972-B1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARM SPA (IT) 2025-01-29 — — EP claimed
EP-4313972-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2024-02-07 — — EP claimed
CN-117062812-A Indoline derivatives as DDR inhibitors 奇斯药制品公司 2023-11-14 — — CN claimed
WO-2022200577-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2022-09-29 — — WO claimed
EP-4313972-B1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARM SPA (IT) 2025-01-29 — — EP disclosed
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-07-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS DDR1, DDR2, DDRGK1 NR2E1 362/4885DDR1 1/4885DDR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback